The potent antitumorigenic activity of the DIM-3,5 analogs are due to several factors, including their activity as dual NR4A1/NR4A2 inverse agonists that inhibit the pro-oncogenic pathway/genes, such as PD-L1, regulated by both receptors in cancer cells [18, 19]. This evidence concerns the gene NR4A1 and cancer.